Literature DB >> 17207422

Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.

Beverley D Glass1, Alison Haywood.   

Abstract

The pharmacist, both in community and hospital pharmacy practice, is often challenged with the preparation of a liquid dosage form not available commercially for paediatric patients, those adults unable to swallow tablets or capsules and patients who must receive medications via nasogastric or gastrostomy tubes. Recognising the lack of information available to healthcare professionals, a general discussion of the various parameters that may be modified in preparing these dosage forms and a tabulated summary of the dosage forms presented in the literature is described, which, although not exhaustive, will provide information on the formulation and stability of the most commonly prepared extemporaneous liquid dosage forms. An extensive survey of the literature and investigation of 83 liquid dosage forms revealed that stability considerations were of concern for only 7.2% of these liquid dosage forms, extemporaneously prepared from the following commercially available products: captopril, hydralazine hydrochloride, isoniazid, levothyroxine sodium, phenoxybenzamine hydrochloride and tetracycline hydrochloride. Inclusion of the antioxidant, sodium ascorbate in the liquid dosage form for captopril resulted in improved stability at 4 degrees C. Hydralazine hydrochloride, isoniazid and phenoxybenzamine hydrochloride were adversely affected due to interactions with excipients in the formulation, while the effect of the preservative in lowering the pH in a levothyroxine sodium mixture resulted in decreased stability. Interestingly, the instability in these formulations is primarily due to interactions between the drug substance and the excipients rather than degradation of the active pharmaceutical ingredient by standard routes such as oxidation, hydrolysis, photolysis or thermolysis. This low percentage however illustrates the low risk associated with these dosage forms investigated. It may be concluded that when considering the safety and efficacy of liquid dosage forms prepared extemporaneously, it is thus important to consider not only the stability of the drug substance but the entire formulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17207422

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  16 in total

1.  Problems with oral formulations prescribed to children: a focus group study of healthcare professionals.

Authors:  Rebecca Venables; Heather Stirling; Hannah Batchelor; John Marriott
Journal:  Int J Clin Pharm       Date:  2015-07-15

2.  Limited Influence of Excipients in Extemporaneous Compounded Suspensions.

Authors:  Eli Dijkers; Valerie Nanhekhan; Astrid Thorissen; Diego Marro; Marta Uriel
Journal:  Hosp Pharm       Date:  2017-07-13

3.  Patient-friendly extemporaneous formulation of bisoprolol: application to stability and bioavailability studies.

Authors:  Soha M El-Masry; Sally A Helmy; Soha A M Helmy; Eman A Mazyed
Journal:  Drug Deliv Transl Res       Date:  2022-10-03       Impact factor: 5.671

4.  Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Authors:  R Court; M T Chirehwa; L Wiesner; N de Vries; J Harding; T Gumbo; G Maartens; H McIlleron
Journal:  Int J Tuberc Lung Dis       Date:  2019-10-01       Impact factor: 2.373

5.  Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions.

Authors:  Hudson C Polonini; Sharlene L Silva; Thalyta R de Almeida; Marcos Antônio F Brandão; Anderson O Ferreira
Journal:  Eur J Hosp Pharm       Date:  2016-03-24

Review 6.  Extemporaneously compounded medicines.

Authors:  James R Falconer; Kathryn J Steadman
Journal:  Aust Prescr       Date:  2017-02-01

Review 7.  Improving policies and practices for the extemporaneous compounding of oral liquid dosage forms in Saudi Arabian hospitals.

Authors:  Imraan Joosub; Zohair Emara; Andy Gray
Journal:  Eur J Hosp Pharm       Date:  2019-08-12

8.  Physical and Chemical Stability of Mycophenolate Mofetil (MMF) Suspension Prepared at the Hospital.

Authors:  Fanak Fahimi; Shadi Baniasadi; Seyed Alireza Mortazavi; Hanie Dehghan; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

9.  Pharmacy compounding primer for physicians: prescriber beware.

Authors:  Sarah Sellers; Wulf H Utian
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

Review 10.  Improving antibiotic prescribing for children in the resource-poor setting.

Authors:  Kirsty Le Doare; Charlotte I S Barker; Adam Irwin; Mike Sharland
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.